These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33609789)

  • 1. Efficacy of complementary treatment with autologous platelet concentrates and/or mesenchymal stem cells in chemical osteonecrosis of the jaw. Systematic review of the literature.
    Escobedo MF; Junquera S; Gonzalez C; Vasatyuk S; Gallego L; Barbeito E; Junquera LM
    J Stomatol Oral Maxillofac Surg; 2022 Feb; 123(1):51-58. PubMed ID: 33609789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review.
    Fortunato L; Bennardo F; Buffone C; Giudice A
    J Craniomaxillofac Surg; 2020 Mar; 48(3):268-285. PubMed ID: 32063481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review.
    Lopez-Jornet P; Sanchez Perez A; Amaral Mendes R; Tobias A
    J Craniomaxillofac Surg; 2016 Aug; 44(8):1067-72. PubMed ID: 27318752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of autologous platelet concentrates in prevention and treatment of medication-related osteonecrosis of the jaws: A systematic review.
    Nowak SM; Sacco R; Mitchell FL; Patel V; Gurzawska-Comis K
    J Craniomaxillofac Surg; 2024 Jun; 52(6):671-691. PubMed ID: 38644092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous platelet concentrates in treatment of medication related osteonecrosis of the jaw.
    Rusilas H; Balčiūnaitė A; Žilinskas J
    Stomatologija; 2020; 22(1):23-27. PubMed ID: 32706343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laser Devices and Autologous Platelet Concentrates in Prevention and Treatment of Medication-Related Osteonecrosis of the Jaws: A Systematic Review.
    Scribante A; Ghizzoni M; Pellegrini M; Pulicari F; Spadari F
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241204
    [No Abstract]   [Full Text] [Related]  

  • 7. The Role of Autologous Platelet Concentrates in the Treatment of Medication-Related Osteonecrosis of the Jaw.
    Ye P; Wei T; Lu ZY; Cai YJ
    J Craniofac Surg; 2021 Mar-Apr 01; 32(2):621-625. PubMed ID: 33704995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical treatment methods of medication-related osteonecrosis of the jaw. A systematic review.
    Zigmantavičius J; Kilinskaitė G; Kubilius R
    Stomatologija; 2022; 24(4):91-99. PubMed ID: 37154420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.
    Voss PJ; Matsumoto A; Alvarado E; Schmelzeisen R; Duttenhöfer F; Poxleitner P
    Odontology; 2017 Oct; 105(4):484-493. PubMed ID: 28220264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review.
    Goker F; Grecchi E; Grecchi F; Francetti L; Del Fabbro M
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2662-2673. PubMed ID: 33829453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weak evidence for the management of medication-related osteonecrosis of the jaw: An overview of systematic reviews and meta-analyses.
    Moraschini V; Calasans-Maia MD; Louro RS; Arantes EBR; Calasans-Maia JA
    J Oral Pathol Med; 2021 Jan; 50(1):10-21. PubMed ID: 32589782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New trends in adjunctive treatment and diagnosis in medication-related osteonecrosis of the jaw: A 10-year review.
    De Santis D; Gelpi F; Luciano U; Zarantonello M; Poscolere A; Modena N; Faccioni P; Causarano G; Finotti M; Zotti F; Magi M; Iurlaro A; Nocini PF; Alberti C; Zangani A; Capocasale G; Donadello D; Nocini R; Bernardello F
    J Biol Regul Homeost Agents; 2020; 34(6 Suppl. 2):37-48. PubMed ID: 33541063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.
    Kuroshima S; Sasaki M; Murata H; Sawase T
    Gerodontology; 2019 Dec; 36(4):313-324. PubMed ID: 31373407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
    Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
    Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols.
    Di Fede O; Canepa F; Panzarella V; Mauceri R; Del Gaizo C; Bedogni A; Fusco V; Tozzo P; Pizzo G; Campisi G; Galvano A
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication-related osteonecrosis of the jaw. Implant presence-triggered osteonecrosis: Case series and literature review.
    Escobedo MF; Cobo JL; Junquera S; Milla J; Olay S; Junquera LM
    J Stomatol Oral Maxillofac Surg; 2020 Feb; 121(1):40-48. PubMed ID: 31035023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up.
    Nisi M; Karapetsa D; Gennai S; Ramaglia L; Graziani F; Gabriele M
    J Craniomaxillofac Surg; 2018 Jul; 46(7):1153-1158. PubMed ID: 29802059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
    Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
    J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study.
    Ristow O; Rückschloß T; Müller M; Berger M; Kargus S; Pautke C; Engel M; Hoffmann J; Freudlsperger C
    J Craniomaxillofac Surg; 2019 Mar; 47(3):491-499. PubMed ID: 30642734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.